Effects of Dapagliflozin on Progression of Alport Syndrome

Inclusion Criteria: * Histologic or genetic confirmation of Alport syndrome; * eGFR ≥ 30 ml/min/1.72m2; * Proteinuria \> 0.5 g/24 h; * Use of an ACE inhibitor or ARB, dose stable for more than 4 weeks; Exclusion Criteria: * Concurrence of other types of kidney disease; * type 1 or type 2 diabetes; * use of other types of sodium-glucose cotransporter 2 inhibitors within the month prior to enrollment, or prior allergy to such drugs; * ACEI combined with ARB, or direct renin inhibitors, aldosterone receptor antagonists; * Uncontrolled hypertension (blood pressure greater than 160/90 mmHg during screening); * Patients undergoing renal transplantation or maintenance dialysis treatment; * Coexist with other serious and/or unstable diseases, such as serious cardiovascular diseases, respiratory diseases, liver diseases or neuropsychiatric diseases; * Patients who are participating in clinical trials of other drugs; * Pregnant or lactating women, or patients who do not want to receive contraception.